Bevacizumab encapsulation into PLGA nanoparticles functionalized with immunouteroglobin-1 as an innovative delivery system for atherosclerosis

Atanasio, Giulia De Negri; Ferrari, Pier Francesco; Baião, Ana; Perego, Patrizia; Sarmento, Bruno; Palombo, Domenico; Campardelli, Roberta

doi:10.1016/j.ijbiomac.2022.08.063

Cited by 13 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanocarriers can be used in targeted delivery of anti-inflammatory agents such as interleukins, especially IL-10. While IL-10 systemic administration has appeared to not be linked to significant reduction in serum levels of cytokines, its targeted release when linked to PLGA appears to induce cap fibrosis and thickness and to reduce the necrosis percentage in the plaque core, inducing plaque stability [ 74 , 75 ]. Preliminary studies showed encouraging results in inflammation reduction when using statins as targeted therapy.…”

Section: Biological and Clinical Effectsmentioning

confidence: 99%

Tissue Engineering and Targeted Drug Delivery in Cardiovascular Disease: The Role of Polymer Nanocarrier for Statin Therapy

et al. 2023

View full text Add to dashboard Cite

Atherosclerosis-related coronary artery disease (CAD) is the leading cause of mortality and morbidity worldwide. This requires effective primary and secondary prevention in reducing the complications related to CAD; the regression or stabilization of the pathology remains the mainstay of treatment. Statins have proved to be the most effective treatment in reducing adverse effects, but there are limitations related to the administration and achievement of effective doses as well as side effects due to the lack of target-related molecular specificity. The implemented technological steps are polymers and nanoparticles for the administration of statins, as it has been seen how the conjugation of drug delivery systems (DDSs) with statins increases bioavailability by circumventing the hepatic–renal filter and increases the related target specificity, enhancing their action and decreasing side effects. Reduction of endothelial dysfunction, reduced intimal hyperplasia, reduced ischemia–reperfusion injury, cardiac regeneration, positive remodeling in the extracellular matrix, reduced neointimal growth, and increased reendothelialization are all drug-related effects of statins enhanced by binding with DDSs. Recent preclinical studies demonstrate how the effect of statins stimulates the differentiation of endogenous cardiac stem cells. Poly-lactic-co-glycolic acid (PLGA) seems to be the most promising DDS as it succeeds more than the others in enhancing the effect of the bound drug. This review intends to summarize the current evidence on polymers and nanoparticles for statin delivery in the field of cardiovascular disease, trying to shed light on this topic and identify new avenues for future studies.

show abstract

Section: Biological and Clinical Effectsmentioning

confidence: 99%

Tissue Engineering and Targeted Drug Delivery in Cardiovascular Disease: The Role of Polymer Nanocarrier for Statin Therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…However, the lack of selectivity/specificity of antineoplastic agents and their distribution to healthy tissues/organs requires the administration in high doses, resulting in significant toxicity and undesirable side effects. [1,2] Bevacizumab (BVZ) is an antiangiogenic monoclonal antibody used in clinic to treat diseases such as corneal neovascularization, [3] atheroma, [4] melanoma, [5] atherosclerosis, [6] macular degeneration, [7] and different types of cancer. [8][9][10][11] It inhibits the vascular endothelial growth factor (VEGF) binding to its tyrosine kinase receptors on the surface of endothelial cells (VEGFR-1 and VEGFR-2).…”

Section: Introductionmentioning

confidence: 99%

“…[12] Similarly, to other anticancer chemotherapeutics, BVZ can trigger several adverse effects, that can be surpassed using targeted delivery systems. [6,[13][14][15] Although the combination of nanotechnology with several chemotherapeutic agents has been largely explored as a promising treatment approach in cancer, nanomedicines translation to the clinic has often been hampered by the absence of reliable and representative cellular models that can provide predictive outcomes on the in vivo efficiency of the formulation. As a result, a high percentage of drugs and nanomedicines fail at later stages of drug development pipeline.…”

Section: Introductionmentioning

confidence: 99%

“…Bevacizumab (BVZ) is an antiangiogenic monoclonal antibody used in clinic to treat diseases such as corneal neovascularization, [ 3 ] atheroma, [ 4 ] melanoma, [ 5 ] atherosclerosis, [ 6 ] macular degeneration, [ 7 ] and different types of cancer. [ 8–11 ] It inhibits the vascular endothelial growth factor (VEGF) binding to its tyrosine kinase receptors on the surface of endothelial cells (VEGFR‐1 and VEGFR‐2).…”

Section: Introductionmentioning

confidence: 99%

“…[ 12 ] Similarly, to other anticancer chemotherapeutics, BVZ can trigger several adverse effects, that can be surpassed using targeted delivery systems. [ 6,13–15 ]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Multicellular Quadruple Colorectal Cancer Spheroids as an In Vitro Tool for Antiangiogenic Potential Evaluation of Nanoparticles

Carvalho

Silveira

Domingues

et al. 2023

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

The encapsulation of bevacizumab (BVZ), angiogenesis inhibitor antibody, into nanocarriers is explored aiming at enhancing its efficacy in colorectal cancer (CRC) treatment while eliminating potential side effects. Still, the translation of such nanomedicines into clinics is not straightforward owing to their preclinical screening in simplistic models, that do not mimic the complexity and heterogeneity of the CRC microenvironment. Herein, the development of a multicellular spheroid of CRC as an advanced preclinical model of CRC capable of screening the antiangiogenic potential of novel nanomedicines is proposed. For that, a quadruple co‐culture is established through the combination of HCT116 cells, human pulmonary microvascular endothelial cell (HPMEC), fibroblasts, and macrophages. It is demonstrated that the developed model displays intrinsic CRC features, such as the organization of cells, expression of tumor microenvironment, extracellular matrix, and the formation of a necrotic core. Moreover, the model is shown to be composed mostly of HCT116 (93%), followed by hypoxia‐inducible factor (3%), HPMEC (3%), and macrophages (1%). Gellan gum/chitosan nanoparticles encapsulating BVZ exhibit superior antiangiogenic properties when compared to free BVZ. Overall, the developed nanoparticles can further be explored as a promising approach in CRC treatment.

show abstract

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Xiao,

Li,

Xiong

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Atherosclerosis, the leading cause of death worldwide, is responsible for ≈17.6 million deaths globally each year. Most therapeutic drugs for atherosclerosis have low delivery efficiencies and significant side effects, and this has hampered the development of effective treatment strategies. Diversified nanomaterials can improve drug properties and are considered to be key for the development of improved treatment strategies for atherosclerosis. The pathological mechanisms underlying atherosclerosis is summarized, rationally designed nanoparticle‐mediated therapeutic strategies, and potential future therapeutic targets for nanodelivery. The content of this study reveals the potential and challenges of nanoparticle use for the treatment of atherosclerosis and highlights new effective design ideas.

show abstract

Bevacizumab encapsulation into PLGA nanoparticles functionalized with immunouteroglobin-1 as an innovative delivery system for atherosclerosis

Cited by 13 publications

References 41 publications

Tissue Engineering and Targeted Drug Delivery in Cardiovascular Disease: The Role of Polymer Nanocarrier for Statin Therapy

Tissue Engineering and Targeted Drug Delivery in Cardiovascular Disease: The Role of Polymer Nanocarrier for Statin Therapy

Multicellular Quadruple Colorectal Cancer Spheroids as an In Vitro Tool for Antiangiogenic Potential Evaluation of Nanoparticles

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Contact Info

Product

Resources

About